NOV 1 6 2000

DECLARATION AND POWER OF AN

As a below named inventor, I hereby dectare that:

My residence, post office address, and consenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint thentor (if plural names are listed below) of the subject maner which is claimed and for which a patent is sought on the invention entired a 18.

TARGETED COMBINATION IMMUNOTHERAPY OF CANCER AND INFECTIOUS DISEASES

the specification of which is attached hereto unless the following box is chacked:

was filed on June 20, 2000 as Umted States Application Number or PCT International Application Number 09/597,580 and was amended on (if applicable).

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the dary to disclose information which is known by me to be material to patentability as defined in Title 37, Code of Federal Regulations § 1.56.

I hereby claim foreign priority benefits under Tule 35. United States Code, § 119(a)-(d) or § 365(b) of any foreign application(s) for patent or inventor's certificate, or § 365(a) of any PCT International application which designated at least one country other than the United States, listed below and have also identified below any foreign application for patent or inventor's certificate, or PCT International application having a filing date before that of the application on which priority is claimed:

PRIOR FOREIGN APPLICATION(S)

NUMBER	COUNTRY	DAY/MONTH/YEAR FILED	PRIORITY CLAIMED
PCT/US97/07395	PCT	May 2, 1997	
			·
			

I hereby claim the benefit under Title 35, United States Code § 119(e) of any United States provisional application(s) listed below.

APPLICATION NO.	FILING DATE
60/017,011	May 3, 1996

I hereby claim the benefit under Title 35. United States Code, § 120 of any United States application(s), or § 365(c) of any PCT International application designating the United States, issued below and, insofar as the subject manner of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of Tule 35, United States Code, § 112, I acknowledge the duty to disclose information which is known by me to be material to paragraph of Tule 35, Code of Federal Regulations § 1.56 which became available between the filing date of the prior application and the national or PCT International filing date of this application.

application serial no.	FOLING DATE	STATUS: PATENTED, PENDING, ABANDONED
(9/184,950	November 3, 1998	Patented June 20, 2000

Ø9-19-00			Y AND LA			+			T-091	P.06/06		
I hereby a Patent and Reg No. Isacson, I Eugene M Sybil Mel 31,298; B Reg. No.	appoint as my d Trademark 28,163; Wil Reg. No. 33,4 Lee, Reg. No. dernhard D. 22,115; Hard	y anorneys, Office com limm T. Ell 715; Mich No. 32,039 5. 22,749; Saxe, Reg. old C. Weg	winctico on the control of the contr	owers of with Steel O. 26,874 minst, Re Lum, Reg C. Peet, R. S; Charles No. 25,258	substitution at phen A. Berr, John J. Feld eg. No. 32,90 No. 25,144: eg. No. 35,79 F. Schull, Re	nd revocation, Reg. No. 29, haus, Reg. No. 44, Kenneth E. Peter G. Mac 2, George E. 8, No. 27,590	to prosecute /68; David A.). 28.822; Pat Krosin, Reg k, Reg. No. / Quillin, Reg.). Richard L.	pplica member mcus D. G No. 25,7 26,001; Bri No. 32,75 Schwarb,	uion and il, Reg.! ranados, 35; Gler an J. Mc 2; Colin Reg. No	transact al No 26,257; Reg. No. in Law, Ro Namara, R G. Sander 25,479;	l busines; Alan I. 33,683; eg. No. eg. No. recock, R Arthur Sc	cantor, Cantor, John P. 34,371; 32,789; Fg. No.
					K Street, N.V 02) 672-5487.							
l hereby believed (punishable jeopardiza	dectare that a to be true; a se by fine or a the validity	ali statement and further imprisonment of the appli	ns made h that these nt, or both canon or a	stein of its statements, under Sei oy parent it	ny own knowl were made verson 1001 of 1 issued thereon	edge are true vith the know! Vitle 18 of the	and that all : ledge that will United States	statements lful false a Code and t	made on tatement hat such	informations and the invital section in the i	n and b ike so n salem	elief are uade are rus ma)
Full Na	me of First h	ventor		T	Signature of	First or Sole	Inventor		Date			
	L. GRIFFIT	Ciffrit	t,			L. Ciff			0	III	0_	
Reside	nce Address	- 4				VV				pzenskip		
	lge h ill Av	_	orristow	m, NJ	07960			Great	Britain			
	ffice Addressistown, N									_		
<u> </u>												
	lame of Secon s J. HANSE				Signature of	First or Sole	Inventor		Date	·		
	ence Addre Vloonraker		dell, LA	70458				1	-	irizenship of Americ	:a	
13	Office Addr II, LA	£28						<u> </u>			····	
<u></u>									T N			
H +	ame of Third 4 M. GOLI		G	·	Signature of	first or Son	inventor		Date	G	~ • •	2.~

Residence Address 330 Pleasant Valley Road, Mendham, New Jersey 07945 Country of Citizenship United States of America

DECLARATION AND POWER OF ATTORN

As a below named inventor, I hereby declare that:

My residence, post office address, and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled ENT &

TARGETED COMBINATION IMMUNOTHERAPY OF CANCER AND INFECTIOUS DISEASES

the specification of which is attached hereto unless the following box is checked:

was filed on June 20, 2000 as United States Application Number or PCT International Application Number 09/597,580 and was amended on (if applicable).

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is known by me to be material to patentability as defined in Title 37, Code of Federal Regulations § 1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, § 119(a)-(d) or § 365(b) of any foreign application(s) for patent or inventor's certificate, or § 365(a) of any PCT International application which designated at least one country other than the United States, listed below and have also identified below any foreign application for patent or inventor's certificate, or PCT International application having a filing date before that of the application on which priority is claimed:

PRIOR FOREIGN APPLICATION(S)

NUMBER	COUNTRY	DAY/MONTH/YEAR FILED PRIC			
PCT/US97/07395	PCT	May 2, 1997			
		,			
2			Charles and the		


I hereby claim the benefit under Title 35, United States Code § 119(e) of any United States provisional application(s) listed below.

APPLICATION NO.	FILING DATE				
60/017,011	May 3, 1996				

I hereby claim the benefit under Title 35, United States Code, § 120 of any United States application(s), or § 365(c) of any PCT International application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of Title 35, United States Code, § 112, I acknowledge the duty to disclose information which is known by me to be material to patentability as defined in Title 37, Code of Federal Regulations § 1.56 which became available between the filing date of the prior application and the national or PCT International filing date of this application:

APPLICATION SERIAL NO.	FILING DATE	STATUS: PATENTED, PENDING, ABANDONED
09/184,950	November 3, 1998	Patented June 20, 2000

BEST AVAILABLE COPY



Address all correspondence to Foley & Lardner, 3000 K Street, N.W., Suite 500, P.O. Box 25696, Washington, D.C. 20007-8696. Address telephone communications to Bernhard D. Saxe at (202) 672-5487.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full Name of First Inventor	Signature of First or Sole Inventor	Date	
Gary L. GRIFFITHS			
	<u> </u>		<u>:</u>
Residence Address		Country of Citizenship Great Britain	
36 Edgehill Avenue, Morristown, NJ	07960	Great Britain	
Post Office Address			***
Morristown, NJ			
Full Name of Second Inventor	Signature of First or Sole Inventor	Date	
Hans J. HANSEN	111 \ 1		
	Ida Stan	- 17000	
Residence Address		Country of Citizenship	
118 Moonraker Drive, Slidell, LA 70458	\mathcal{O}	United States of America	ı
- ·			
Post Office Address			3-
Slidell, LA			
Full Name of Third Inventor	Signature of First or Sole Inventor	Date	
David M. GOLDENBERG	Signature of First of Sole inventor	Date	
·			
Residence Address		Country of Citizenship	
330 Pleasant Valley Road, Mendham, Nev	w Jersey 07945	United States of America	ı .
Post Office Address			
Mendham, New Jersey			

BEST AVAILABLE COPY

114

Applicant or Patentee: Gary L. GRIFFITHS et al.

Serial or Patent No.: <u>09/597,580</u> Atty. Dkt. No. 018

Filed or Issued: June 20, 2000

TARGETED COMBINATION IMMUNOTHERAPY OF CANCER AND

INFECTIOUS DISEASES

VERIFIED STATEMENT (DECLARATION) CLAIMING SMALL ENTITY STATUS (37 CFR 1.9(f) AND 1.27 (c)) — SMALL BUSINESS CONCERN

I hereby declare that I am

the owner of the small business concern identified below:

(X) an official of the small business concern empowered to act on behalf of the concern identified below:

NAME OF CONCERN: IMMUN

IMMUNOMEDICS, INC.

ADDRESS OF CONCERN: 300 American Road

Morris Plains, New Jersey 07950

I hereby declare that the above-identified small business concern qualifies as a small business concern as defined in 13 CFR 121.3-18 and reproduced in 37 CFR 1.9(d), for purposes of paying reduced fees under section 41(a) and (b) of Title 35, United States Code, in that the number of employees of the concern, including those of its affiliates, does not exceed 500 persons. For purposes of this statement, (1) the number of employees of the business concern is the average over the previous fiscal year of the concern of the persons employed on a full-time, part-time or temporary basis during each of the pay periods of the fiscal year, and (2) concerns are affiliates of each other when either, directly or indirectly, one concern controls or has the power to control the other, or a third party or parties controls or has the power to control both.

I hereby declare that rights under contract or law have been conveyed to and remain with the small business concern identified above with regard to the invention, entitled TARGETED COMINBATION IMMUNOTHERAPY OF CANCER AND INFECTIOUS DISEASES by inventor(s) Gary L. Griffiths et al. described in

() the specification filed herewith

(X) application serial no. <u>09/597,580</u>, filed <u>June 20, 2000</u>

() patent no. , issued

If the rights held by the above-identified small business concern are not exclusive, each individual, concern or organization having rights to the invention is listed below* and no rights to the invention are held by any person, other than the inventor, who would not qualify as an independent inventor under 37 CFR 1.9(c) if that person made the invention, or by any concern which would not qualify as a small business concern under 37 CFR 1.9(d) or a nonprofit organization under 37 CFR 1.9(e). * NOTE: Separate verified statements are required from each named person, concern or organization having rights to the invention averring to their status as small entities: (37 CFR 1.27)

NAME: ADDRESS: () INDIVIDUAL	() SMALL BUSINESS CONCERN	() NONPROFIT CORPORATION
NAME: ADDRESS: () INDIVIDUAL	() SMALL BUSINESS CONCERN	() NONPROFIT CORPORATION

Attorney Docket No. U. \$\int 34/0987\$

Page 2 of 2

I acknowledge the duty to file, in this application or patent, notification of any change in status resulting in loss of entitlement to small entity status prior to paying, or at the time of paying, the earliest of the issue fee or any maintenance fee due after the date on which status as a small entity is no longer appropriate: (37 CFR 1.28(b)).

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application, any patent issuing thereon, or any patent to which this verified statement is directed.

NAME OF PERSO	N SIGNING:X_	DAVID	M.	GOLDENE	BERG		•
TITLE OF PERSO				sicman 1	OCED		_
ADDRESS OF PER	rson signing	: Smymon	علاك	300 America	Ad.	Morris	Plains
SIGNATURE:X	H/W			DATE:X7	10192	NTO	7950
,	0			7	77		- 700